GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » EBITDA Margin %

Aditxt (Aditxt) EBITDA Margin % : -14,500.00% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aditxt EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aditxt's EBITDA for the three months ended in Mar. 2024 was $-11.60 Mil. Aditxt's Revenue for the three months ended in Mar. 2024 was $0.08 Mil. Therefore, Aditxt's EBITDA margin for the quarter that ended in Mar. 2024 was -14,500.00%.


Aditxt EBITDA Margin % Historical Data

The historical data trend for Aditxt's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt EBITDA Margin % Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - -41,863.81 -2,658.24 -3,946.98

Aditxt Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,585.32 -1,853.85 -6,417.74 -9,587.65 -14,500.00

Competitive Comparison of Aditxt's EBITDA Margin %

For the Biotechnology subindustry, Aditxt's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aditxt's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aditxt's EBITDA Margin % falls into.



Aditxt EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aditxt's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-25.458/0.645
=-3,946.98 %

Aditxt's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-11.6/0.08
=-14,500.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aditxt  (NAS:ADTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Aditxt EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Aditxt's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aditxt (Aditxt) Business Description

Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
Charles Athle Nelson director 11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp 10 percent owner 787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes officer: Chief Legal Officer and GC 737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley officer: PRINCIPAL ACCOUNTING OFFICER 2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge director C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna officer: CHIEF OPERATING OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne officer: CHIEF FINANCIAL OFFICER BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony director LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna director, officer: CHIEF EXECUTIVE OFFICER 871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang director, officer: CHIEF INNOVATION OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354

Aditxt (Aditxt) Headlines

From GuruFocus